CalciMedicaCALC
Market Cap: $44.5M
About: CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. Its proprietary technology targets the inhibition of calcium release-activated calcium channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are no approved therapies.
Employees: 13
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
5% more funds holding
Funds holding: 20 [Q1] → 21 (+1) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
5.38% less ownership
Funds ownership: 33.06% [Q1] → 27.67% (-5.38%) [Q2]
20% less capital invested
Capital invested by funds: $14.8M [Q1] → $11.8M (-$2.99M) [Q2]
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
HC Wainwright & Co. Joseph Pantginis 38% 1-year accuracy 102 / 272 met price target | 383%upside $20 | Buy Reiterated | 13 Aug 2024 |
Oppenheimer Leland Gershell 57% 1-year accuracy 24 / 42 met price target | 383%upside $20 | Outperform Maintained | 10 Jul 2024 |
HC Wainwright & Co. Joseph Pantginis 38% 1-year accuracy 102 / 272 met price target | 383%upside $20 | Buy Reiterated | 9 Jul 2024 |
HC Wainwright & Co. Joseph Pantginis 38% 1-year accuracy 102 / 272 met price target | 383%upside $20 | Buy Reiterated | 27 Jun 2024 |